For GA, secondary to AMD
NAVIGATING PATIENT SUPPORT
Get to know the ApellisAssist® program️
ApellisAssist is a program offering a range of support services.
Insurance
support
- Benefits verification
- Prior Authorization (PA) and appeals information
- Annual reverification of insurance coverage for enrolled patients
Patient financial
assistance
- The SYFOVRE Co-pay Programa
- The Patient Assistance Program
- Referrals to independant co-pay assistance foundations
A dedicated
online portal
- Enroll patients in the ApellisAssist program
- Access your patient documents
- Track patient status through the iAssist platform
Apellis Care
Educators
- Trained to provide ongoing support
- Information on financial assistance options
- Address barriers to access
aThe SYFOVRE Co-pay Program is for eligible patients who are enrolled in the ApellisAssist program, are commercially insured, and are not covered under government insurance programs such as Medicare, Medicaid, VA/DoD, or TRICARE. Apellis reserves the right to modify or terminate the program at any time without notice.
In 2024, ApellisAssist helped more than 45,000 eligible patients navigate access to SYFOVRE.1
Accessing the ApellisAssist program through the iAssist portal
iAssist is a web-based platform that enables you to access ApellisAssist services. Through iAssist, practices are able to:
- Enroll patients online
- Easily track patient statuses across multi-site practices
- Click to chat for portal technical support
- Obtain eHIPAA consent online
Getting started with iAssist
Looking to get started with the iAssist Portal? Watch this helpful video to learn about registering your practice and enrolling patients using the Portal.
Register your practice (1:28)
Options for prescriber credentialing (3:48)
Enroll a patient (5:08)
Options to gain electronic patient consent (6:37)
Ability to upload documents within the enrollment workflow (7:20)
INDICATION: SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
SELECT SAFETY INFORMATION: SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation.
Additional Important Safety Information for SYFOVRE will be covered at the end of this video.
Hello, and welcome to getting started with iAssist.
Once your office decides SYFOVRE is the right treatment for your patient, the ApellisAssist program can help patients gain access to the product.
To help introduce iAssist, meet our guide, Eileen, an eye care practice manager. In this video, we’ll follow Eileen as she gets her practice started using iAssist. You’ll learn how to register your practice, enroll a patient in the ApellisAssist program through iAssist, and take a tour through available services and resources. Note that if you have already registered your practice with iAssist and have an account, feel free to move ahead in this video to “Chapter 2: Enroll a patient.” If you have not registered, let’s start there.
Before Eileen dives in, please note that iAssist contains protected health information, and iAssist users should have appropriate authorizations or permissions to access such information. There is also an important point to consider when registering, especially if your practice has multiple offices or locations.
You can proceed using either of 2 options. In the first option, you would create one parent iAssist account for your entire practice, then add each office as a location under that main account. This method allows the account administrator and authorized users to view and manage all of your practice’s patients enrolled in iAssist across all your offices from a single parent account. In the second option, each office or location in your practice would create its own iAssist account with separate organization information. This method allows multiple accounts for your practice but the administrators and users of the separate accounts can only view and manage the enrolled patients aligned with their specific office or location.
Whether you create one iAssist account for your practice or several, the registration process remains the same. On the next several screens, we’ll view Eileen’s monitor as she goes through the registration process.
And that’s it. We’ve seen Eileen sign up for a new account, register her practice, add and verify a prescriber, and log in to iAssist. Thanks, Eileen.
Enrolling your patients in the ApellisAssist program provides them with a support system that may help with insurance support, educational resources, and financial assistance for eligible patients. Now that Eileen has registered and logged in, we’ll view her monitor and follow along again as she enrolls one of her practice’s patients using iAssist.
And with that, Eileen has registered her practice’s first patient in the ApellisAssist program through iAssist. For each new patient your practice enrolls through iAssist, you’ll proceed through the same process. Thanks again, Eileen.
Well, we’ve come to the end of Eileen’s tour through the iAssist introductory video. Thanks again, Eileen, and thank you for viewing. Hopefully it’s been helpful in getting you and your patients off to a great start on the access and support journey with the ApellisAssist program.
INDICATION
SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
- SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation
WARNINGS AND PRECAUTIONS
- Endophthalmitis and Retinal Detachments
- Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
- Retinal Vasculitis and/or Retinal Vascular Occlusion
- Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
- Neovascular AMD
- In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
- Intraocular Inflammation
- In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
- Increased Intraocular Pressure
- Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.
ADVERSE REACTIONS
- Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.
Please see full Prescribing Information for more information.
If you are not able to enroll your patients online, you have the option to download and fax the completed enrollment form to 888-405-6966.
We recognize that you are the expert in your patients’ care. The ApellisAssist program is here to provide support by helping patients overcome potential access barriers to treatment.
AMD=age-related macular degeneration; GA=geographic atrophy; HIPAA=Health Insurance Portability and Accountability Act.
Reference: 1.Data on file. Apellis Pharmaceuticals, Inc; 2024.
